Navigation Links
Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
Date:7/31/2008

MONTREAL, July 31 /PRNewswire/ -- Aegera Therapeutics Inc. is pleased to announce the dosing of the first patient in a fifth phase 1 and 2 clinical oncology study of AEG35156, a second generation antisense therapeutic targeting XIAP, a key member of the Inhibitor of Apoptosis protein family.

The study, made possible, in part, by funding from The Leukemia & Lymphoma Society, is entitled "A Phase 1-2, Multicenter, Open-Label Study of the X- Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Follicular Lymphoma." It is being conducted at the Princess Margaret Hospital (PMH) located in Toronto, Ontario, and is led by Principal Investigator Dr. Christine Chen, with co-Principal Investigators Dr. Aaron Schimmer and Dr. Joe Brandwein, all from the PMH's Department of Hematology and Oncology.

The primary objective of this study is to determine the recommended dose of AEG35156 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and follicular lymphoma (FL), and to determine the safety profile and response rate to AEG35156 in these patient populations.

"Preliminary evidence of activity in lymphoma was observed in phase 1 studies with AEG35156," stated Dr. Jacques Jolivet, Aegera's VP Clinical. "This clinical trial will specifically study the role played by XIAP knockdown in inducing antitumor activity in CLL, SLL and FL."

"Our clinical program around AEG35156 continues to expand and broaden as we seek to move this therapeutic forward to approval," added Aegera's President and Chief Executive Officer, Dr. Michael J. Berendt. "By adding these lymphoma indications to AEG35156's ongoing phase 1 and 2 studies in leukemia (AML), pancreatic, breast, and non-small cell lung cancer, we continue to seek to position AEG35156 as an important therapeutic option that could address important unme
'/>"/>

SOURCE Aegera Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
2. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
3. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
4. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
5. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
8. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
9. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
10. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
11. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... BROOKFIELD, Wis. , March 27, 2015 /PRNewswire/ ... 40,000 unit shipments of incontinence devices for women. ... terrific, but the most gratifying part is the ... receive from women whose lives have been positively ... , president of InControl. InControl recently ...
(Date:3/27/2015)... 27, 2015  Johnson & Johnson (NYSE: JNJ ) ... (Eastern Time) on Thursday, April 23, 2015, from the State ... Investors and other interested parties may access the live ... at www.jnj.com and clicking on the webcast icon. ... be made available a few hours after the live meeting ...
(Date:3/27/2015)... YORK , March 27, 2015 /PRNewswire/ ... the leading source of health information, today ... the new National Action Plan for ... President Obama emphasized the urgency and importance ... on national and global health.    ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... Healthcare Network today announced that Outreach Services has agreed ... company will be named Cardon Outreach, and will be ... core business of both companies is providing revenue cycle ... their patient populations.  Cardon Outreach will serve over 500 ...
... Mich., Jan. 24, 2012 Validation & Compliance Institute (VCI) announces ... and Food companies are struggling with: How can ... breaking the bank? Experts have found that the ... for knowledge retention.  That way there are no excuses.  Big companies ...
Cached Medicine Technology:Outreach Services Merger With Cardon Healthcare Creates Largest Provider of Eligibility Services to Hospitals 2Validation & Compliance Institute Provides Affordable Online FDA Training 2
(Date:3/28/2015)... Coffee could not only perk you up ... gum disease, researchers have found. , They found that those ... contains antioxidants. Antioxidants fight gum disease. Does coffee, then, help ... Univ. Henry M. Goldman School of Dental Medicine explored in ... of the Journal of Periodontology. , “This is the first ...
(Date:3/28/2015)... 2015 Take a bite of warm, ... action. Acids tumble into the stomach, ready to break ... structure lets these acids run amok, triggering a burning ... symptom. More than 60 million Americans have heartburn at ... heartburn starts, and how it can be stopped. , ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs ... shopping on UniWigs during the Easter Holidays from today ... promotion on April Fools’ Day. , As the winter ... the corner. Easter Festival, with religious origins to countries ... holiday after Christmas. The best wig provider, UniWigs, would ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 An article ... problem which could prove critical to organizations that deal ... a critical aspect of data security, is worsening . ... data security report, every major category out of the ... penetration testing. “With all the craziness that has gone ...
(Date:3/28/2015)... 2015 One in three young athletes ... presented today at the American Orthopaedic Society for Sports ... the long term success of surgery for patients aged ... data from 242 patients who underwent ACL reconstruction between ... MBBS, FRACS, from North Sydney Orthopaedic and Sports Medicine ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
... 2008 The Arthritis Foundation announces the 2008 winners ... in arthritis. The recipients, Dr. Gerard Karsenty of the ... of Rockefeller University received the award for their continued ... diseases. , Dr. Karsenty is recognized for his ...
... The Food Allergy & Anaphylaxis Network (FAAN) today named ... Founder Anne Munoz-Furlong, who is retiring. , ... extensive knowledge of anaphylaxis, a severe, potentially fatal allergic ... of Marketing, she led the marketing team and strategic ...
... steroids effective against plantar fasciitis, researchers say , , ... say they,ve developed a fast, effective, non-invasive treatment ... fasciitis. , Using a combination of "dry-needling" and ... their approach achieved a 95 percent success rate ...
... Today, more than 740 children will die of AIDS. In fact, nearly ... , December 1 is World AIDS Day, a day ... A central theme for World AIDS Day 2008 is You Can ... people together to talk about HIV as well as helping dispel the myths ...
... Condell Health Network, parent corporation of Condell Medical ... disclosing that it received improper Medicare and Medicaid payments ... States and the State of Illinois$36 million as a ... J. Fitzgerald, U.S. Attorney for the Northern District of ...
... SIDS and this may be why, researchers say , , MONDAY, ... blood pressure that persists during the first six months of ... prone to sudden infant death syndrome (SIDS), Australian researchers suggest. ... profound drop in blood pressure during sleep, from which the ...
Cached Medicine News:Health News:FAAN Names New CEO 2Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3Health News:In Support of World AIDS Day, FHSSA Announces New Partnerships That Include the First In-Country Partnerships in Namibia and The Gambia 2Health News:Condell Health Network and Medical Center to Pay $36 Million Settlement After Self-Reporting Possible Health-Care Fraud 2Health News:Preemies' Low Blood Pressure Linked to SIDS 2Health News:Preemies' Low Blood Pressure Linked to SIDS 3
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
This fixed-volume digital micropipet is used to accurately measure and transfer 50 microliters of solution....
50L...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
Medicine Products: